Delivery Order SPE2DB24D2003-SPE2DB25FXLM1
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Procrit 40,000 units/ml vials, a pharmaceutical product used in treating anemia and related conditions. This firm fixed-price delivery order has a ceiling value of $4,092.76 and is scheduled for completion by August 8, 2025. The contract is not set-aside and represents a competitive award to AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a $6,890.79 delivery order to AmerisourceBergen Drug Corp for 10,000 units per milliliter of Procrit, a pharmaceutical product commonly used to treat anemia. This firm fixed price delivery order was competitively awarded with no set-aside designation and is scheduled for completion by September 18, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,991.78 firm-fixed-price delivery order is for the supply of 40,000 units of the drug Procrit (40,000 units/mL) and does not have a set-aside designation. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a significant $999,999,999 Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a $12,414.44 firm fixed price delivery order to AmerisourceBergen Drug Corp for 10,000 units/mL of Procrit (epoetin alfa), a medication used to treat anemia. The order was placed on September 4, 2025, with an ultimate completion date of September 5, 2025, and will be performed at the contractor's location in Conshohocken, Pennsylvania. This is a non-set-aside competitive award, reflecting AmerisourceBergen's qualification to meet federal pharmaceutical...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $16,542.20 fixed-price delivery order is for the procurement of 40,000 units of the drug Procrit with a strength of 40,000 units/mL. The award is part of a larger $999,999,999.00 Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical. This IDC...
- AmerisourceBergen Drug Corp was awarded a delivery order on August 13, 2025, for 20,000 units of Procrit (epoetin alfa) 20,000 unit/2 mL vials, valued at $6,626.50. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of August 14, 2025. The award is performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, and is funded through the Medical Supply Chain, which operates under the Department of Defense. Procrit is a critical...
- This is a federal delivery order award valued at $1,334.02 to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) Medical Supply Chain. The contract is for the supply of 10,000-unit vials of the pharmaceutical drug Procrit (epoetin alfa), a medication used to treat anemia. The delivery order is part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999, that enables the agency to...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,155.74 firm fixed-price delivery order is for the supply of 20,000 units/mL of the medication PROCRIT. The contract has an ultimate completion date of January 5, 2024 and does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery...
- This federal contract award, valued at $5,514.10, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of Procrit 40,000 units/mL vials, a specialty medication. There is no set-aside designation, indicating the contract was competitively awarded. Amerisourcebergen Drug Corp is a subsidiary of Cencora, Inc., which holds two significant Indefinite Delivery Contracts (IDCs) with the DLA and the...
- This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the delivery of PROCRIT 40,000 UNITS/ML VIALML to the Defense Logistics Agency (DLA). The $5,947.54 firm fixed-price delivery order has a completion date of July 15, 2024. The award is not set aside and is part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at up to $999,999,999 through December 2025. Under this single-award IDC, Amerisourcebergen provides a...
- SPE2DB24D2003Indefinite Delivery Contract
- SPE2DB24D2003-SPE2DB25FXLM1Delivery Order
This delivery order, valued at $1,148.21, awards Amerisourcebergen Drug Corp the supply of Procrit 40,000 units/ml vials under a firm fixed price contract with the Defense Logistics Agency (DLA). The award was made on August 7, 2025, with an ultimate completion date of August 8, 2025, with performance taking place at the contractor's facility in Conshohocken, Pennsylvania. This non-set-aside contract represents a competitive award to the pharmaceutical distributor for a critical injectable medication commonly used in military and federal healthcare systems for treating anemia-related conditions. This delivery order is a child contract issued against Amerisourcebergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a ceiling value of $999,999,999.00 and extends through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the contractor to supply an extensive range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including specialty medications, brand-name and generic drugs, vaccines, and related medical commodities across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 8/7/25 |